| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1016/J.TRSL.2006.11.011 |
| P698 | PubMed publication ID | 17320797 |
| P50 | author | Giovanni Gasbarrini | Q22004484 |
| Luca Miele | Q49363519 | ||
| Antonio Grieco | Q51119909 | ||
| P2093 | author name string | Alessandra Forgione | |
| P2860 | cites work | Antioxidant defence mechanisms: new players in the pathogenesis of non-alcoholic steatohepatitis? | Q79265901 |
| Hepatic MRI for fat quantitation: its relationship to fat morphology, diagnosis, and ultrasound | Q80341556 | ||
| Portal fibrosis and hepatic steatosis in morbidly obese subjects: A spectrum of nonalcoholic fatty liver disease | Q80565685 | ||
| A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease | Q81100393 | ||
| Associations between liver histology and severity of the metabolic syndrome in subjects with nonalcoholic fatty liver disease | Q81691178 | ||
| Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease | Q81926258 | ||
| Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C | Q24563264 | ||
| Liver fibrosis in overweight patients | Q28145482 | ||
| History, heterogeneity, developmental biology, and functions of quiescent hepatic stellate cells | Q28190388 | ||
| Steatohepatitis: a tale of two "hits"? | Q29547771 | ||
| Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity | Q29614914 | ||
| Design and validation of a histological scoring system for nonalcoholic fatty liver disease | Q29614930 | ||
| High density synthetic oligonucleotide arrays | Q29616560 | ||
| Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease | Q29619334 | ||
| Nonalcoholic fatty liver disease | Q29619354 | ||
| Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease | Q33263279 | ||
| Cytokines and fibrogenesis | Q33697040 | ||
| Cellular distribution of transforming growth factor-beta 1 and procollagen types I, III, and IV transcripts in carbon tetrachloride-induced rat liver fibrosis | Q34252968 | ||
| Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease | Q34382683 | ||
| Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. | Q34390093 | ||
| CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis | Q34432561 | ||
| Candidate gene case-control association studies: advantages and potential pitfalls | Q34459045 | ||
| Hepatic steatosis and very low density lipoprotein secretion: the involvement of apolipoprotein E. | Q34459818 | ||
| The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies | Q45209585 | ||
| Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study | Q45737816 | ||
| Systemic markers of lipid peroxidation and antioxidants in patients with nonalcoholic Fatty liver disease | Q46397581 | ||
| Serum laminin, type IV collagen and hyaluronan as fibrosis markers in non-alcoholic fatty liver disease | Q46511322 | ||
| Hepatic gene expression in patients with obesity-related non-alcoholic steatohepatitis | Q46515459 | ||
| Polymorphisms in the transforming growth factor-beta gene (TGF-beta) and the risk of advanced alcoholic liver disease | Q46702701 | ||
| Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease | Q46920588 | ||
| Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid. | Q47876312 | ||
| Sampling variability of liver fibrosis in chronic hepatitis C. | Q48583601 | ||
| Serum markers detect the presence of liver fibrosis: a cohort study. | Q51983072 | ||
| Non-invasive markers to predict the liver fibrosis in non-alcoholic fatty liver disease. | Q53605149 | ||
| NASH: a hidden and silent fibroser finally revealed? | Q53856506 | ||
| Pro-fibrotic polymorphisms predictive of advanced liver fibrosis in the severely obese. | Q53910016 | ||
| Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. | Q55033443 | ||
| Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease | Q58622754 | ||
| Non-alcoholic fatty liver disease: a multicentre clinical study by the Italian Association for the Study of the Liver | Q62607261 | ||
| Transforming growth factors beta 1 and alpha in chronic liver disease. Effects of interferon alfa therapy | Q67984653 | ||
| Characterization of pathogenic and prognostic factors of nonalcoholic steatohepatitis associated with obesity | Q73246068 | ||
| Transforming growth factor-beta gene expression in normal and fibrotic rat liver | Q73287222 | ||
| Serum YKL-40 is increased in patients with hepatic fibrosis | Q74012591 | ||
| Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis | Q74027130 | ||
| Nonalcoholic fatty liver disease | Q74119103 | ||
| Association between microsomal triglyceride transfer protein gene polymorphism and the biological features of liver steatosis in patients with type II diabetes | Q74319412 | ||
| Nonalcoholic steatohepatitis | Q74424858 | ||
| Soluble tumor necrosis factor receptors in chronic hepatitis C: a correlation with histological fibrosis and activity | Q74586915 | ||
| Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients | Q77318114 | ||
| Diagnostic potential of circulating TIMP-1 and MMP-2 as markers of liver fibrosis in patients with chronic hepatitis C | Q77369404 | ||
| Molecular regulation of hepatic fibrogenesis | Q77619568 | ||
| Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study | Q77761919 | ||
| NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States | Q78560735 | ||
| The metabolic syndrome as a predictor of nonalcoholic fatty liver disease | Q34467576 | ||
| Nonalcoholic steatosis and steatohepatitis. V. Mitochondrial dysfunction in steatohepatitis. | Q34502805 | ||
| Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. | Q34525065 | ||
| Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. | Q34544284 | ||
| Activation of hepatic stellate cells--a key issue in liver fibrosis | Q34565618 | ||
| Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference | Q35115696 | ||
| Long term prognosis of fatty liver: risk of chronic liver disease and death. | Q35596463 | ||
| Immune response towards lipid peroxidation products as a predictor of progression of non-alcoholic fatty liver disease to advanced fibrosis | Q35597601 | ||
| Non-alcoholic fatty liver and insulin resistance: a cause-effect relationship? | Q35716511 | ||
| Non-alcoholic steatohepatitis: review of a growing medical problem | Q35739295 | ||
| Evaluation of liver fibrosis: a concise review | Q35794328 | ||
| Review article: the evolving role of liver biopsy | Q35845834 | ||
| Insulin resistance and the pathogenesis of nonalcoholic fatty liver disease | Q35872177 | ||
| The potential role of genes in nonalcoholic fatty liver disease | Q35872188 | ||
| Association of differentially expressed genes with activation of mouse hepatic stellate cells by high-density cDNA microarray | Q36067494 | ||
| Fibrosis in chronic liver diseases: diagnosis and management | Q36074820 | ||
| NASH: a mitochondrial disease | Q36122708 | ||
| In vitro and in vivo association of transforming growth factor-beta 1 with hepatic fibrosis | Q36220782 | ||
| Non-alcoholic fatty liver disease: current concepts and management strategies. | Q36415491 | ||
| Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo | Q37031936 | ||
| Absence of sterol regulatory element-binding protein-1 (SREBP-1) ameliorates fatty livers but not obesity or insulin resistance in Lep(ob)/Lep(ob) mice | Q38290693 | ||
| Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population | Q39693472 | ||
| Stimulation and proliferation of primary rat hepatic stellate cells by cytochrome P450 2E1-derived reactive oxygen species | Q40757681 | ||
| Seminars in medicine of the Beth Israel Hospital, Boston. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies | Q40911465 | ||
| Molecular mechanisms of liver fibrogenesis--a homage to the role of activated fat-storing cells | Q40940134 | ||
| Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors | Q41208203 | ||
| Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. | Q43494872 | ||
| Hepatic gene expression in histologically progressive nonalcoholic steatohepatitis | Q43542965 | ||
| Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities | Q43552270 | ||
| Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese | Q43662697 | ||
| High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis | Q43755024 | ||
| Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease | Q43879331 | ||
| Apolipoprotein synthesis in nonalcoholic steatohepatitis | Q43933950 | ||
| In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases | Q44036833 | ||
| Complement factor 5 is a quantitative trait gene that modifies liver fibrogenesis in mice and humans | Q44042948 | ||
| The utility of radiological imaging in nonalcoholic fatty liver disease. | Q44116674 | ||
| Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model | Q44151781 | ||
| Genome-wide analysis of hepatic fibrosis in inbred mice identifies the susceptibility locus Hfib1 on chromosome 15. | Q44231634 | ||
| Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values | Q44458156 | ||
| A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. | Q44527614 | ||
| Hepatic mitochondrial beta-oxidation in patients with nonalcoholic steatohepatitis assessed by 13C-octanoate breath test | Q44627897 | ||
| Hepatic fibrosis as wound repair: a progress report | Q45111395 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | liver disease | Q929737 |
| metabolic dysfunction–associated steatotic liver disease | Q1546498 | ||
| steatohepatitis | Q2335423 | ||
| non-alcoholic steatohepatitis | Q28692677 | ||
| non-alcoholic fatty liver | Q66299798 | ||
| P304 | page(s) | 114-125 | |
| P577 | publication date | 2007-03-01 | |
| P1433 | published in | Translational Research | Q15761127 |
| P1476 | title | Noninvasive assessment of fibrosis in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) | |
| P478 | volume | 149 |
| Q46177222 | A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis |
| Q46578297 | A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH). |
| Q41836078 | Effect of Daisaikoto on Expressions of SIRT1 and NF-kappaB of Diabetic Fatty Liver Rats Induced by High-Fat Diet and Streptozotocin |
| Q42685890 | Genome-based nutrition: an intervention strategy for the prevention and treatment of obesity and nonalcoholic steatohepatitis |
| Q53358958 | In vivo (1)H-MRS hepatic lipid profiling in nonalcoholic fatty liver disease: an animal study at 9.4 T. |
| Q38948643 | Liver tissue metabolic profiling and pathways of non-alcoholic steatohepatitis in rats |
| Q37149405 | Nonalcoholic fatty liver disease: an overview of current insights in pathogenesis, diagnosis and treatment |
| Q64989197 | Prediction of VEGF-C as a Key Target of Pure Total Flavonoids From Citrus Against NAFLD in Mice via Network Pharmacology. |
| Q33514542 | Proteomic analysis of serum in patients with non-alcoholic steatohepatitis using matrix-assisted laser desorption ionization time-of-flight mass spectrometry |
| Q33886918 | Proteomic and genomic studies of non-alcoholic fatty liver disease--clues in the pathogenesis |
| Q51791871 | Serum levels of hyaluronic acid and tissue metalloproteinase inhibitor-1 combined with age predict the presence of nonalcoholic steatohepatitis in a pilot cohort of subjects with nonalcoholic fatty liver disease. |
| Q87164941 | Usefulness of T1 mapping on Gd-EOB-DTPA-enhanced MR imaging in assessment of non-alcoholic fatty liver disease |
| Q37028786 | Utility of Ultrasound, Transaminases, and Visual Inspection to Assess Nonalcoholic Fatty Liver Disease in Bariatric Surgery Patients |
Search more.